Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
ACRO BIOMEDICAL CO., LTD.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
High return on equity (26.1%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
ACRO BIOMEDICAL CO., LTD. shows $0.00 in FY2025 revenue, and 26.1% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001622996, latest 10-Q filed 2026-05-05) · EODHD · rules-based read · as of 6/18/2026, 12:42:40 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.20M | $659K | $0.00 | $0.00 | $0.00 |
| Gross profit | $260K | $141K | $0.00 | — | — |
| Operating income | -$7.69M | -$15.9M | -$8.80M | -$38.0K | -$154K |
| Net income | -$7.70M | -$15.9M | -$8.81M | -$42.3K | -$101K |
| Diluted EPS | — | -$0.26 | -$0.15 | $0.00 | $0.00 |
| Net margin | -642.8% | -2410.2% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median